# US 2009/0221607 A1 · Piperazine Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221607 A1
- Document ID: US20090221607A1
- Status: Published application
- Kind: A1
- Application number: 12/223,444
- Filed: 2007-01-23
- Published: 2009-09-03
- Earliest claimed: 2006-02-15
- Assignees: M's Science Corporation
- Inventors: Connie L. Sun; Xiaoyuan Li
- Web page: https://patentgrep.com/patent/US20090221607A1

## CPC

- C07D 295/088: to an acyclic saturated chain
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of general formula (I) in which R1, A1, A2 and R2 have any of the meanings given in the specification, have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A compound of general formula (I)
in which: —
R1 represents a phenyl group that is substituted by one or two fluorine atoms;
A1 represents (CH2)m or (CH2)m-1C(═O);
m is 2, 3, 4 or 5;
A2 represents (CH2)n or C(═O)(CH2)n-1;
n is 2, 3, 4 or 5; and
R2 represents a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkylsulfonyl group, a halo(1-4C)alkoxy group, and a halo(1-4C)alkylsulfonyl group;
or a pharmaceutically acceptable salt thereof,
or a stereoisomeric form or a polymorphic form of said compound or of said salt;
provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl.

### Claim 17 (depends on 16)

A compound as claimed in claim 16, in R1 represents a 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, or 2,4-difluorophenyl group.

### Claim 18 (depends on 16, 17)

A compound as claimed in claim 16 or claim 17 in which m is 2.

### Claim 19 (depends on 16, 17)

A compound as claimed in claim 16 or claim 17 in which m is 3.

### Claim 20 (depends on 16, 17)

A compound as claimed in any one of claims 16 and 17 in which A1 represents (CH2)m.

### Claim 21 (depends on 16, 17)

A compound as claimed in any one of claims 16 and 17 in which n is 2.

### Claim 22 (depends on 16, 17)

A compound as claimed in any one of claims 16 and 17 in which n is 3.

### Claim 23 (depends on 16, 17)

A compound as claimed in any one of claims 16 and 17 in which A represents (CH2)n.

### Claim 24

A compound of general formula (I)
in which: —
R1 represents a phenyl group that is substituted by one or two fluorine atoms;
A1 represents (CH2)m or (CH2)m-1C(═O);
m is 2, 3, 4 or 5;
A represents (CH2)n or C(═O)(CH2)n-1;
n is 2, 3, 4 or 5; and
R2 represents a phenyl group that is substituted by one or two substituents selected independently from a fluorine atom, a cyano group, a fluoro(1-4C) alkyl group, a (1-4C)alkylsulfonyl group, a fluoro(1-4C)alkoxy group and a fluoro(1-4C)alkylsulfonyl group;
or a pharmaceutically acceptable salt thereof,
or a stereoisomeric form or a polymorphic form of said compound or of said salt;
provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl.

### Claim 25 (depends on 17)

A compound as claimed in claim 17, in which R2 represents a substituent selected from the group consisting of 2-fluorophenyl, 4-fluorophenyl, 3-cyanophenyl, 4-cyanophenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-methylsulfonylphenyl, 4-methylsulfonylphenyl, 3-trifluoromethylsulfonylphenyl, and 4-trifluoromethylsulfonylphenyl.

### Claim 26 (depends on 25)

A compound as claimed in claim 25 in which R2 represents 2-fluorophenyl.

### Claim 27 (depends on 25)

A compound as claimed in claim 25 in which R2 represents 4-fluorophenyl.

### Claim 28

A compound selected from the group consisting of:
1,4-Bis-[2-(2-fluorophenoxy)ethyl]piperazine dihydrochloride,
1,4-Bis-[3-(4-fluorophenoxy)propyl]piperazine,
1,4-Bis-[3-(2-fluorophenoxy)propyl]piperazine dihydrochloride,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-fluorophenoxy)propyl]piperazine dihydrochloride,
and 2-(4-Fluorophenoxy)-1-{4-[2-(4-fluorophenoxy)acetyl]piperazin-1-yl}-ethanone,
or a pharmaceutically acceptable salt of the selected compound, including a stereoisomeric form or a polymorphic form of said compound or of said salt.

### Claim 29

A compound selected from the group consisting of:
4-(2-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
4-(2-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
4-(2-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
3-(2-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
3-(2-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
3-(2-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
4-(3-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
4-(3-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
4-(3-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
3-(3-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
3-(3-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
3-(3-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(2-Difluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine, and
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
or a pharmaceutically acceptable salt of the selected compound, or a stereoisomeric form or a polymorphic form of said compound or of said salt.

### Claim 30

A process for preparing a compound of the general formula (I)
in which: —
R1 represents a phenyl group that is substituted by one or two fluorine atoms;
A1 represents (CH2)m or (CH2)m-1C(═O);
m is 2, 3, 4 or 5;
A represents (CH2)n or C(═O)(CH2)n-1;
n is 2, 3, 4 or 5; and
R1 represents a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkylsulfonyl group, a halo(1-4C)alkoxy group, and a halo(1-4C)alkylsulfonyl group;
or a pharmaceutically acceptable salt thereof,
or a stereoisomeric form or a polymorphic form of said compound or of said salt;
provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl,
comprising a process selected from the group consisting of:
a) reacting a compound of general formula (II)
in which each of Z1 and Z2 independently represents a leaving atom or group, or a corresponding compound in which one or more substituents on R2 are protected, with a compound of general formula (III)
R1—O-A1-NH2 (III);
b) reacting a compound of general formula (IV)
in which each of Z3 and Z4 independently represents a leaving atom or group, with a compound of general formula (V)
H2N-A2-O—R2 (V)
or a corresponding compound in which one or more substituents on R2 are protected;
c) reacting a compound of general formula (VI)
with a compound of general formula (VII)
Z5-A2-O—R2 VII)
in which Z5 represents a leaving atom or group;
d) reacting a compound of formula (VIII)
with a compound of general formula (IX)
R1—O-A1-Z6 (IX)
in which Z6 represents a leaving atom or group; and
e) for a compound of formula (I) in which A1 represents (CH2)m and A2 represents (CH2)n, reducing a corresponding compound of formula (I) in which A1 represents (CH2)m-1C(═O) and/or A2 represents C(═O)(CH2)n-1;
the selected process followed by removing any protecting group, and, optionally, forming a pharmaceutically acceptable salt.

### Claim 31 (depends on 16, 17, 24, 28)

A pharmaceutical composition, which comprises a compound as claimed in any one of claims 16, 17, 24, 28, or 29 and a pharmaceutically acceptable diluent or carrier.

### Claim 32

A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound of general formula (I)
in which: —
R1 represents a phenyl group that is substituted by one or two fluorine atoms;
A1 represents (CH2)m or (CH2)m-1C(═O);
m is 2, 3, 4 or 5;
A represents (CH2)n or C(═O)(CH2)n-1;
n is 2, 3, 4 or 5; and
R2 represents a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkylsulfonyl group, a halo(1-4C)alkoxy group and a halo(1-4C)alkylsulfonyl group;
or a pharmaceutically acceptable salt thereof, or a stereoisomeric form or a polymorphic form of said compound or of said salt,
provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl.

### Claim 33 (depends on 32)

The method according to claim 32 which comprises administering to said patient an effective amount of a compound of the general formula (I) in which R1 represents a 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, or 2,4-difluorophenyl group.

### Claim 34 (depends on 32, 33)

A method of treating a condition as in any one of claims 32 and 33, wherein m is 2 in the compound of general formula (I).

### Claim 35 (depends on 32, 33)

A method of treating a condition as in any one of claims 32 and 33, wherein m is 3 in the compound of general formula (I).

### Claim 36 (depends on 32, 33)

A method of treating a condition as in any one of claims 32 and 33, wherein A1 represents (CH2)m in the compound of general formula (I).

### Claim 37 (depends on 32, 33)

A method of treating a condition as in any one of claims 32 and 33, wherein n is 2 in the compound of general formula (I).

### Claim 38 (depends on 32, 33)

A method of treating a condition as in any one of claims 32 and 33, wherein n is 3 in the compound of general formula (I).

### Claim 39 (depends on 32, 33)

A method of treating a condition as in any one of claims 32 and 33, wherein A2 represents (CH2)n in the compound of general formula (I).

### Claim 40

A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound of general formula (I)
in which: —
R1 represents a phenyl group that is substituted by one or two fluorine atoms;
A1 represents (CH2)m or (CH2)m-1C(═O);
m is 2, 3, 4 or 5;
A represents (CH2)n or C(═O)(CH2)n-1;
n is 2, 3, 4 or 5; and
R2 represents a phenyl group that is substituted by one or two substituents selected independently from a fluorine atom, a cyano group, a fluoro(1-4C) alkyl group, a (1-4C)alkylsulfonyl group, a fluoro(1-4C)alkoxy group and a fluoro(1-4C)alkylsulfonyl group;
or a pharmaceutically acceptable salt thereof,
or a stereoisomeric form or a polymorphic form of said compound or of said salt;
provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl.

### Claim 41 (depends on 40)

A method of treating a condition as claimed in claim 40, in which R2 of the compound represents a substituent selected from the group of 2-fluorophenyl, 4-fluorophenyl, 3-cyanophenyl, 4-cyanophenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-methylsulfonylphenyl, 4-methylsulfonylphenyl, 3-trifluoromethylsulfonylphenyl, and 4-trifluoromethylsulfonylphenyl.

### Claim 42 (depends on 41)

A compound as claimed in claim 41, in which R2 of the compound represents 2-fluorophenyl.

### Claim 43 (depends on 41)

A compound as claimed in claim 41, in which R2 of the compound represents 4-fluorophenyl.

### Claim 44

A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound selected from the group consisting of:
1,4-Bis-[2-(2-fluorophenoxy)ethyl]piperazine dihydrochloride,
1,4-Bis-[3-(4-fluorophenoxy)propyl]piperazine,
1,4-Bis-[3-(2-fluorophenoxy)propyl]piperazine dihydrochloride,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-fluorophenoxy)propyl]piperazine dihydrochloride,
and 2-(4-Fluorophenoxy)-1-{4-[2-(4-fluorophenoxy)acetyl]piperazin-1-yl}-ethanone,
or a pharmaceutically acceptable salt of the selected compound,
or a stereoisomeric form or a polymorphic form of said compound or of said salt.

### Claim 45

A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound selected from the group consisting of:
4-(2-{4-[2-(4-Fluorophenoxy)ethyl]-piperazin-1-yl}ethoxy)benzonitrile,
4-(2-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
4-(2-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
3-(2-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
3-(2-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
3-(2-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
4-(3-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
4-(3-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
4-(3-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
3-(3-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
3-(3-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
3-(3-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(2-Difluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-methanesulfonylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine, and
1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
or a pharmaceutically acceptable salt of the selected compound, or a stereoisomeric form,
or a polymorphic form of said compound or of said salt.
